Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach

Clinical and Experimental Rheumatology

Fausto Salaffi¹  Michele Intorcia¹  Andrea Bellatreccia¹  Danielle Dupont¹  Gianni Leardini¹  Ariel Beresniak¹  Marco A. Cimmino¹ 

关键词: Rheumatoid arthritis;    cost-effectiveness;    modelling;    abatacept;    rituximab;    Abatacept;    rheumatoid arthritis;    cost-effectiveness;    Rituximab;    rheumatoid arthritis;    cost-effectiveness;   

DOI  :  

学科分类：医学（综合）

来源: Pacini Editore SpA

【 摘 要 】

OBJECTIVES: The objective of this study is to assess cost-effectiveness of different biologic strategies in patients with moderate-to-severe active RA after an insufficient response to anti-TNF agents within the context of the Italian healthcare system. METHODS: Simulation models were developed allowing for potential biologic therapy switch at each 6-month time point in case of an insufficient response to the previous biologic agent. Biologic treatments included etanercept, abatacept, adalimumab, rituximab or infliximab. Effectiveness criteria for these models were defined as achieving a state of low disease activity (LDAS) [DAS28 ≤3.2] or remission (RS) [DAS28

【 授权许可】

Unknown